- Home
- LGCY vs XGN Comparison
LGCY vs XGN Comparison
Compare LGCY & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- XGN
- Stock Information
- Founded
- LGCY 2009
- XGN 2002
- Country
- LGCY United States
- XGN United States
- Employees
- LGCY N/A
- XGN N/A
- Industry
- LGCY
- XGN Medical Specialities
- Sector
- LGCY
- XGN Health Care
- Exchange
- LGCY NYSE
- XGN Nasdaq
- Market Cap
- LGCY 117.7M
- XGN 138.3M
- IPO Year
- LGCY 2024
- XGN 2019
- Fundamental
- Price
- LGCY $11.05
- XGN $7.39
- Analyst Decision
- LGCY Strong Buy
- XGN Strong Buy
- Analyst Count
- LGCY 2
- XGN 3
- Target Price
- LGCY $10.65
- XGN $9.00
- AVG Volume (30 Days)
- LGCY 97.1K
- XGN 275.1K
- Earning Date
- LGCY 05-15-2025
- XGN 07-29-2025
- Dividend Yield
- LGCY N/A
- XGN N/A
- EPS Growth
- LGCY 21.53
- XGN N/A
- EPS
- LGCY 0.62
- XGN N/A
- Revenue
- LGCY $58,970,210.00
- XGN $56,724,000.00
- Revenue This Year
- LGCY $33.77
- XGN $18.92
- Revenue Next Year
- LGCY $24.88
- XGN $14.78
- P/E Ratio
- LGCY $17.76
- XGN N/A
- Revenue Growth
- LGCY 37.92
- XGN 1.78
- 52 Week Low
- LGCY $3.60
- XGN $1.78
- 52 Week High
- LGCY $12.30
- XGN $7.95
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- XGN 59.57
- Support Level
- LGCY N/A
- XGN $6.81
- Resistance Level
- LGCY N/A
- XGN $7.50
- Average True Range (ATR)
- LGCY 0.00
- XGN 0.33
- MACD
- LGCY 0.00
- XGN 0.03
- Stochastic Oscillator
- LGCY 0.00
- XGN 88.17
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.